| Study | Study type | System | Main COX5B-related finding | Quantitative/statistical data reported in extracted text | Publication date | URL |
|---|---|---|---|---|---|---|
| Oliveira et al., *Genes* | In silico mutation analysis | Breast cancer datasets/public databases | COX5B was highlighted among nine Complex IV structural genes with potential impact on breast cancer biology; authors argue Complex IV subunits merit follow-up as markers/contributors in BC. (pqac-00000007) | 2,107 samples analyzed; four variants with significant pathogenic potential were reported overall, but no COX5B-specific effect size/statistic was provided in extracted text. (pqac-00000007) | 2023-07 | https://doi.org/10.3390/genes14071465 |
| Nývltová et al. | Mechanistic review of human COX biogenesis | Human mitochondrial complex IV assembly | COX5B is contextualized as one of the 11 nucleus-encoded accessory subunits of mammalian cytochrome c oxidase; review emphasizes accessory subunits/assembly factors coordinate biogenesis and prevent reactive intermediates, supporting COX5B’s likely assembly/stabilization role rather than direct catalysis. (pqac-00000013) | No COX5B-specific statistics; review-level mechanistic synthesis only. (pqac-00000013) | 2023-01 | https://doi.org/10.25376/hra.21892989 |
| Mühleip et al., *Nature* | Structural biology (cryo-EM/cryo-ET, MD) | Mitochondrial respiratory supercomplex | Provides a 2023 structural advance on respiratory supercomplex organization and membrane curvature; relevant to COX5B because it advances current understanding of Complex IV-containing supercomplex architecture, though the extracted text did not report a COX5B-specific mechanistic conclusion. (pqac-00000011) | 5.8-MDa supercomplex, 150 proteins, 311 bound lipids in the reported structure; no COX5B-specific quantitative result in extracted text. (pqac-00000011) | 2023-03 | https://doi.org/10.1038/s41586-023-05817-y |
| Schmidt et al., *IJMS* | Transcriptomic/signaling study | Proliferating human cardiac stem cells exposed to human serum | RNA-seq identified COX5B among potential NF-κB target genes involved in serum-induced proliferation of human cardiac stem cells, linking COX5B expression to proliferative signaling in this cell context. (paper-search result summary; no dedicated context ID beyond corpus mention) | Extracted corpus text states COX5B was “significantly” expressed/identified as a potential NF-κB target, but no fold change or p-value for COX5B was available in the extracted evidence shown here. | 2024-03 | https://doi.org/10.3390/ijms25073593 |
| Xie et al., *Frontiers in Pharmacology* | Mendelian randomization + PPI network analysis | Diabetic ketoacidosis (DKA) using GWAS/openGWAS data and 64 mitochondrial proteins | COX5B was identified as one of the mitochondrial proteins showing a negative causal relationship with DKA, interpreted by the authors as a potentially protective factor/therapeutic target candidate. (pqac-00000006, pqac-00000016) | 64 mitochondrial proteins tested; increased mtDNA copy number significantly reduced DKA risk overall, but no COX5B-specific OR/CI/p-value was available in the extracted pages. (pqac-00000006, pqac-00000016) | 2024-10 | https://doi.org/10.3389/fphar.2024.1448505 |
| Castillo-Armengol et al., *Diabetologia* | snRNA-seq + proteomics | Mouse hypothalamus in a type 2 diabetes/recurrent hypoglycaemia model | COX5B was included among oxidative-phosphorylation-related genes/proteins altered in hypothalamic adaptation to recurrent hypoglycaemia, consistent with broader mitochondrial/OXPHOS remodeling. | AH group n=33 vs RH group n=37 for glucagon analysis; glucagon 94.5±9.2 ng/L vs 59.0±4.8 ng/L, p<0.001 overall, but no COX5B-specific fold change/statistic was reported in extracted text. | 2024-11 | https://doi.org/10.1007/s00125-023-06043-x |
| Xie et al. / broader 2024 disease-target framing | Translational inference from MR | Clinical/metabolic disease context | The authors recommend targeting mitochondrial function and suggest proteins including COX5B as candidate intervention points, illustrating a real-world translational use case for COX5B-centered hypothesis generation. (pqac-00000006, pqac-00000016) | No intervention trial data; evidence is causal-inference/statistical genetics rather than direct therapeutic testing. (pqac-00000006, pqac-00000016) | 2024-10 | https://doi.org/10.3389/fphar.2024.1448505 |


*Table: This table summarizes 2023-2024 COX5B-related developments identified in the retrieved corpus, emphasizing study context, main findings, and whether quantitative COX5B-specific statistics were available. It is useful for distinguishing direct evidence on COX5B from broader Complex IV or mitochondrial-context studies.*